Effective Reduction of Acne-induced Post-inflammatory Hyperpigmentation with the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol)
Main Article Content
Keywords
Thiamidol, Post-Inflammatory Hyperpigmentation, Acne
Abstract
Objective: Post-inflammatory hyperpigmentation (PIH) is a major cosmetic concern especially in individuals with darker skin complexion. Unfortunately, treatment with anti-inflammatory ingredients alone does not prevent the development of hyperpigmented spots. Recently, Thiamidol (isobutylamido thiazolyl resorcinol) was described as a very potent inhibitor of human tyrosinase. The objective of this research was to investigate the potential of Thiamidol-based formulations to prevent PIH induced by acne-induced epidermal wounding.
Methods: The effect of skin care formulations containing Thiamidol on acne-related PIH was investigated in two studies; a vehicle-controlled, double-blinded, randomized clinical study, and a clinical observational study. Both studies had a duration of 3 months and included assessments of clinical photography, clinical grading and melanin index measurements.
Results: Subjects’ self-grading demonstrated that Thiamidol significantly improved the visibility of acne-induced hyperpigmentation compared to the vehicle treatment. A skin care regimen with Thiamidol significantly improved acne-related PIH over 12 weeks shown by Mexameter measurements, expert grading, self-grading and clinical photography.
Conclusion: Thiamidol represents a safe and effective ingredient for cosmetic products against post-inflammatory hyperpigmentation.
References
2. Callender VD, St. Surin-Lord S, Davis EC, et al. Am J Clin Dermatol. 2011;12(2):87-99.
3. Grimes PE. Semin Cutan Med Surg. 2009;28(2):77-85.
4. Del Bino S, Duval C, Bernerd F. Int J Mol Sci. 2018;19(9):2668.
5. Cestari TF, Dantas LP, Boza JC. An Bras Dermatol. 2014;89(1):11-25.
6. Davis EC, Callender VD. J Clin Aesthet Dermatol. 2010;3(7):20-31.
7. Abad-Casintahan F, Chow SK, Goh CL, et al. J Dermatol. 2016;43(7):826-828.
8. Mishra SN, Dhurat RS, Deshpande DJ, et al. Int J Dermatol. 2013;52(4):413-417.
9. Westerhof W, Kooyers TJ. J Cosmet Dermatol. 2005;4(2):55-59.
10. Simmons BJ, Griffith RD, Bray FN, et al. Am J Clin Dermatol. 2015;16(3):205-212.
11. Mann T, Gerwat W, Batzer J, et al. J Invest Dermatol. 2018;138(7):1601-1608.
12. Mann T, Scherner C, Röhm KH, et al. Int J Mol Sci. 2018;19(3):690.
13. Arrowitz C, Schoelermann AM, Mann T, et al. J Invest Dermatol. 2019;139(8):1691-1698.e6.
14. Briganti S, Camera E, Picardo M. Pigment Cell Res. 2003;16(2):101-110.
15. Espin JC, Varon R, Fenoll LG, et al. Eur J Biochem. 2000;267(5):1270-1279.
16. Garcia-Molina F, Hiner AN, Fenoll LG, et al. J Agric Food Chem. 2005;53(9):3702-3709.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.